Sansure's profit slumps on price cuts and tax hike despite new product approvals
First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.
This is the biggest new negative force on the stock and explains the core earnings deterioration.
Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.
Negative cash flow is a new financial red flag that adds to the profit decline.
New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.
These approvals are the main positive pipeline news that could offset weak current earnings over time.
Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.
This captures both the positive capital return and the negative overhang from forced share sales.